Elly Gerald Stoica

Array ( [id] => 15023461 [patent_doc_number] => 20190322735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST [patent_app_type] => utility [patent_app_number] => 16/283694 [patent_app_country] => US [patent_app_date] => 2019-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46628 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -125 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16283694 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19441214 [patent_doc_number] => 12091455 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-17 [patent_title] => Compositions for modulation of a TREM or TREML protein and methods of use [patent_app_type] => utility [patent_app_number] => 16/969707 [patent_app_country] => US [patent_app_date] => 2019-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 38 [patent_no_of_words] => 36185 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 371 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16969707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715691 [patent_doc_number] => 20190248909 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => MODULATING AUTOIMMUNE DIABETES BY REDUCING OR REMOVING THE RESIDENT MACROPHAGES OF THE ISLETS OF LANGERHANS [patent_app_type] => utility [patent_app_number] => 16/275013 [patent_app_country] => US [patent_app_date] => 2019-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19104 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16275013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14403889 [patent_doc_number] => 20190167788 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => Composition and Method for Treating Cancer [patent_app_type] => utility [patent_app_number] => 16/271388 [patent_app_country] => US [patent_app_date] => 2019-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5812 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16271388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621795 [patent_doc_number] => 20210040448 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => CLOSED-SYSTEM MANUFACTURING PROCESS FOR CAR-T CELLS [patent_app_type] => utility [patent_app_number] => 16/965964 [patent_app_country] => US [patent_app_date] => 2019-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8228 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965964 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14681645 [patent_doc_number] => 20190239937 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => Augmentation of Abscopal Effect of Cryotherapy and other Tumor Cell Death by Anti-angiogenic and Anti-tumor Vaccination [patent_app_type] => utility [patent_app_number] => 16/266499 [patent_app_country] => US [patent_app_date] => 2019-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3921 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16266499 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16956253 [patent_doc_number] => 11060097 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-13 [patent_title] => Immunotherapy methods using anti-PD-L1 antibodies in combination with EGFR1 targeted-TGF-beta immunomodulatory fusion proteins [patent_app_type] => utility [patent_app_number] => 16/263157 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 8364 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16263157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15784953 [patent_doc_number] => 10626183 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-21 [patent_title] => IFN-g-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof [patent_app_type] => utility [patent_app_number] => 16/255690 [patent_app_country] => US [patent_app_date] => 2019-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 33 [patent_no_of_words] => 26967 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 197 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16255690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16650005 [patent_doc_number] => 10927168 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab [patent_app_type] => utility [patent_app_number] => 16/248762 [patent_app_country] => US [patent_app_date] => 2019-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 74 [patent_figures_cnt] => 98 [patent_no_of_words] => 43379 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16248762 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16696689 [patent_doc_number] => 10947270 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => Targeted prodrug cytosine deaminase fusion carrier and application thereof [patent_app_type] => utility [patent_app_number] => 16/247489 [patent_app_country] => US [patent_app_date] => 2019-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 79 [patent_no_of_words] => 13719 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 187 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16247489 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14534599 [patent_doc_number] => 20190202921 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => Anti-CSF1R Antibody and Anti PD-1 Antibody Combination Therapy for Cancer [patent_app_type] => utility [patent_app_number] => 16/243510 [patent_app_country] => US [patent_app_date] => 2019-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63787 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16243510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17043829 [patent_doc_number] => 11096989 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-24 [patent_title] => Synergistic tumor treatment with an extended pharmacokinetic IL-2 and integrin-binding-Fc fusion protein [patent_app_type] => utility [patent_app_number] => 16/230466 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 39 [patent_no_of_words] => 32369 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16230466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14467861 [patent_doc_number] => 20190185573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => AGENTS THAT NEUTRALIZE IL-3 SIGNALLING AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/231029 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16231029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14464675 [patent_doc_number] => 20190183977 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 16/226262 [patent_app_country] => US [patent_app_date] => 2018-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26321 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16226262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16756628 [patent_doc_number] => 10975166 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-13 [patent_title] => Inhibitory antibodies against MMP-14 [patent_app_type] => utility [patent_app_number] => 16/223943 [patent_app_country] => US [patent_app_date] => 2018-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 41 [patent_no_of_words] => 36556 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 416 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16223943 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16688355 [patent_doc_number] => 20210070831 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => POOLING SIGNALING AND COSTIMULATORY DOMAINS IN FLEXIBLE CAR DESIGN [patent_app_type] => utility [patent_app_number] => 16/772183 [patent_app_country] => US [patent_app_date] => 2018-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10649 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16772183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16435675 [patent_doc_number] => 20200353000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => PROFILING AND TREATMENT OF MYC-ASSOCIATED CANCERS [patent_app_type] => utility [patent_app_number] => 16/771617 [patent_app_country] => US [patent_app_date] => 2018-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20219 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16771617 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14130195 [patent_doc_number] => 20190099487 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-04 [patent_title] => METHODS OF USING INTERLEUKIN-10 FOR TREATING DISEASES AND DISORDERS [patent_app_type] => utility [patent_app_number] => 16/217611 [patent_app_country] => US [patent_app_date] => 2018-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27151 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16217611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14406919 [patent_doc_number] => 20190169303 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => Humanized Anti-OX40 Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/215263 [patent_app_country] => US [patent_app_date] => 2018-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51989 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16215263 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16590581 [patent_doc_number] => 10899831 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity [patent_app_type] => utility [patent_app_number] => 16/204220 [patent_app_country] => US [patent_app_date] => 2018-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 74 [patent_figures_cnt] => 98 [patent_no_of_words] => 42581 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16204220 [rel_patent_id] =>[rel_patent_doc_number] =>)